Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells
Anxo Rio-Vilariño, Aiora Cenigaonandia-Campillo, Ana García-Bautista, Pedro A. Mateos-Gómez, Marina I. Schlaepfer, Laura del Puerto-Nevado, Oscar Aguilera, Laura García-García, Carlos Galeano, Irene de Miguel, Juana Serrano-López, Natalia Baños, María Jesús Fernández-Aceñero
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHippo pathway signaling and YAP/TAZ
Correction to: British Journal of Cancer 10.1038/s41416-024-02649-z, published online 11 March 2024
In this article, the funding section needs be rephrased. Currently it reads:
“This work was supported by the grant PI19/01231 funded by AEI and the European Union. A.R-V contract was funded by the program “CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD (PFIS)”, grant FI20/00213 from the Instituto de Salud Carlos III (ISC-III) and co-funded by the European Union associated with the project PI19/01231.”
It should be updated to:
“This work was supported by the grant PI19/01231 funded by AEI and the European Union. A.R-V contract was funded by the program “CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD (PFIS)”, grant FI20/00213 from the Instituto de Salud Carlos III (ISC-III) and co-funded by the European Union (ERDF/ESF, “A way to make Europe”/“Investing in your future”) associated with the project PI19/01231.
The original article has been updated.